BACKGROUND: The effect of multiple infusions of infliximab (INF), a  chimeric anti- @entity5 necrosis factor alpha antibody, on the concentration of hexosaminidase (HEX) activity in a  synovial cell culture derived from @entity1 synovial inflamed fluid obtained from @entity1 suffering from @entity309 ( @entity309 ) has been evaluated. OBJECTIVES: The aim of this study was to prove INF efficacy in @entity309 . MATERIAL AND METHODS: Inflamed synovial fluid was taken from @entity309 @entity1 (a  study group) and @entity1 who had undergone knee trauma within 7  days (a  control group). The following solutions of infliximab were used: 40, 60 and 140    g/mL. Determination of the concentration of HEX activity in cell cultures was performed after 24, 48, 72 and 96 h  of infliximab administration. To identify synoviocytes in cell culture immunohistochemical staining with vimentin and pancytokeratin was performed. RESULTS: A  predominance of fibroblast-like synovial cells has been observed in the study group. In the control group the concentration of HEX activity without adding infliximab to the cell culture was 283.00 nkat/mL. After 96 h  of incubation with infliximab, the concentrations of HEX activity in cultured synoviocytes according to infliximab doses of 40, 60 and 140    g/mL were respectively: 280.00, 271.50 and 293.50 nkat/mL. In the study group, the concentration of HEX activity without adding infliximab to the cell culture was 542.27 nkat/mL. The final concentrations of HEX activity of cultured fibroblast-like synovial cells measured after 96 h  of incubation with infliximab were: 471.72, 498.27 and 556.72 nkat/mL, according to infliximab doses of 40, 60 and 140    g/mL. In all groups (besides the infliximab concentration of 140    g/mL after 96 h  of incubation), the level of concentration of HEX activity was significantly higher in the study group compared to the control group, irrespective of infliximab concentration and time of infliximab incubation. CONCLUSIONS: Infliximab changes the concentration of HEX activity depending on the drug dose and time of administration.

Fibroblast-Like Synovial Cells in XXXX - the Impact of Infliximab on Hexosaminidase Activity.

@entity5 :: ('MESH:D009369', 'Disease') :: ['tumor'] @entity1 :: ('9606', 'Species') :: ['human', 'patients'] @entity309 :: ('MESH:D001172', 'Disease') :: ['rheumatoid arthritis', 'RA']
@entity309 :: (MESH:D001172,Disease) :: ['Rheumatoid Arthritis']
